Novel gene therapy for drug-resistant melanoma: Synergistic combination of PTEN plasmid and BRD4 PROTAC-loaded lipid nanocarriers
Patients suffering from BRAF mutant melanoma have tumor recurrence within merely 7 months of treatment with a potent BRAF inhibitor (BRAFi) like vemurafenib. It has been proven that diverse molecular pathways driving BRAFi resistance converge to activation of c-Myc in melanoma. Therefore, we identif...
Sábháilte in:
Príomhchruthaitheoirí: | , , , |
---|---|
Formáid: | LEABHAR |
Foilsithe / Cruthaithe: |
Elsevier,
2024-09-01T00:00:00Z.
|
Ábhair: | |
Rochtain ar líne: | Connect to this object online. |
Clibeanna: |
Cuir clib leis
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!
|
Ar líne
Connect to this object online.3rd Floor Main Library
Gairmuimhir: |
A1234.567 |
---|---|
Cóip 1 | Ar fáil |